Abstract 2177P
Background
Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment but they often carry a wide spectrum of immune-related adverse events (irAE), which might preclude treatment continuation. Biomarkers predictive of irAE would be useful to better select and manage patients for ICI therapy.
Methods
This retrospective analysis included patients treated with ≥3 cycles of ICI, regardless of the primary tumour, in a single hospital in Portugal, from January 2017 to December 2022. Data regarding irAE was collected, as well as baseline neutrophil-lymphocyte (NLR), platelet-lymphocyte (PLR) ratios and systemic imune-inflammation index (SII, given by platelets*neutrophils/lymphocytes). Scores were categorized using cutoff values described in literature, as NLR≥3, PLR≥180 and SII≥750. Descriptive analysis was performed using SPSS®. Association between the scores and irAE was analyzed using logistic regression.
Results
141 patients were included. 87% were males and the median age was 66. Most common diagnoses were non-small cell lung cancer (75%) and head and neck cancer (7%) and main ICI were pembrolizumab (53%), durvalumab (18%) and nivolumab (16%), with a 10 cycles median. 137 (97%) patients developed irAE: digestive (24%), cutaneous (20%), flu-like symptoms (12%) and others. 15% had grade ≥3 irAE, leading to ICI suspension in 11%. 55% died during follow-up, most due to disease progression, 1 due to irAE. Median inflammation scores were 3,5 (NLR), 175 (PLR) and 818 (SII). A statistically significant correlation was found between NLR≥3 and gastrointestinal (p 0,007, OR 0,375) and respiratory AE (p 0,023, OR 3,608); SII≥750 and gastrointestinal (p=0,015, OR=0,413), respiratory (p 0,020, OR 0,255) and musculoskeletal AE (p 0,015, OR 0,342); PLR≥180 and hepatic (p 0,045, OR 2,934) and musculoskeletal AE (p 0,045, OR 0,446). There was no correlation with the presence of grade ≥3 AEs nor with survival.
Conclusions
In this study baseline inflammation scores were associated with some irAEs but not with survival as described in literature. These findings support a correlation between systemic inflammation status and tolerability to immunotherapy and show the value of inflammatory scores as potential biomarkers of irAE.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
ULS Matosinhos - Hospital Pedro Hispano.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2140P - Short-term quality-of-life after metastases-directed SBRT: Results of the prospective ESTRO & EORTC OligoCare cohort
Presenter: Daniela Greto
Session: Poster session 07
2141P - Symptom burden and health-related quality of life (HRQoL) in platinum-resistant or -refractory ovarian cancer (PROC): A systematic literature review (SLR)
Presenter: Nikhila Indukuri
Session: Poster session 07
2142P - Criteria for the choice of therapeutic ceiling in the hospitalized oncology patient: Healthcare impact of the multidisciplinary committee with the Intensive Care Unit (ICU)
Presenter: María Esperanza Guirao García
Session: Poster session 07
2143P - Mortality within 30 days after last dose of intravenous systemic anti-cancer therapy: Single-center, one-year, retrospective analysis
Presenter: Osman Sutcuoglu
Session: Poster session 07
2144P - The PRognostic Oncologic Plantology (PROP) website tool predicts 30-day mortality in hospitalized cancer patients on treatment
Presenter: Oriol Mirallas
Session: Poster session 07
2145P - Thromboembolic disease associated with cyclin-dependent kinase inhibitors in patients with breast cancer
Presenter: Javier López Robles
Session: Poster session 07
2146P - Cancer-associated thrombosis clinic: Experience of the Medical Oncology Department of a hospital in Spain
Presenter: Laura Ortega Morán
Session: Poster session 07
2147P - Thrombotic recurrence and bleeding complications in non-small cell lung carcinoma (NSCLC) patients with venous thromboembolism (VTE)
Presenter: Irene Gonzalez Caraballo
Session: Poster session 07
2148P - Venous thromboembolism (VTE) in patients with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitors
Presenter: Lorenzo Gervaso
Session: Poster session 07
2149P - Catheter-related thrombosis in cancer patients: Data from the registry of thrombosis and neoplasia of SEOM (TESEO)
Presenter: Francisco Pelegrín Mateo
Session: Poster session 07